Professional
Added to YB: 2024-04-02
Pitch date: 2024-03-25
CVAC [bullish]
CureVac N.V.
+57.81%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
Market Cap
$1.0B
Pitch Price
$3.20
Price Target
15.40 (+205%)
Dividend
N/A
EV/EBITDA
2.68
P/E
5.38
EV/Sales
1.33
Sector
Biotechnology
Category
growth
Show full summary:
CureVac N.V.: CureVac Provides Risk-Tolerant Investors With Pure-Play Exposure to mRNA Candidates
CVAC: Developing mRNA vaccines & therapies. Early-stage pipeline includes 2nd-gen COVID vax w/ GSK (35% PoS), flu, rabies & cancer. Extreme uncertainty but $15.40 FVE offers upside for risk-tolerant LT investors. Key risks: competition, low pricing power, reimbursement pressure.
Read full article (8 min)